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1.1. Cigarette smoking prevalence, mortality, and
morbidity
In this review, “smoking” refers to chronic smoking of to-
bacco in the form of cigarettes. Approximately 2 billion peo-
ple worldwide use tobacco products, mostly in the form of
cigarettes, with tobacco smoking–related diseases resulting
in at least 4 million global deaths per year [1]. There are
an estimated 44 million active smokers in the United States
[2]; however, the actual prevalence of smoking in the United
States may be underestimated, particularly in younger adults
and females [3]. In the United States, smoking-related dis-
ease accounts for about one in every five deaths, which equa-
tes to more than 440,000 annual deaths, and smoking-related
morbidity results in annual direct health-care expenditures
and productivity loss of $193 billion [2,4]. The greatest
smoking-related mortality is increasingly apparent among
economically disadvantaged groups, which, in the United
States, includes a disproportionate numberof ethnicminorities
[5,6]. Over the past 5 years, the prevalence of adult smokers in
the United States has remained constant, and the ratio of
former to never smokers (quit ratio) has not changed since
1998 [7]. In 2009, the US Food and Drug Administration
(FDA) enacted the Family Smoking Prevention and Tobacco
Control Act (TCA) to regulate the manufacture, distribution,
and marketing of tobacco products to protect the public from
smoking-related mortality and morbidity (Public Law 111-
31; www.fda.gov/TobaccoControlAct). However, despite the
implementation of the TCA, millions of Americans continue
to smoke.
Smoking prevalence in active duty US Armed Services
personnel is approximately 31% overall [8] and 35% in
active duty personnel with high combat exposure [9],
which are 11% and 15% higher, respectively, than in the
general US population. Smoking among US military
personnel is associated with lower productivity and levels
of physical fitness, as well as increased risk for injury dur-
ing training and impaired rate of wound healing (see Refs.
[8,10,11] for review); consequently, smoking lowers
combat readiness of our active duty personnel [11]. Smok-
ing is among the strongest predictors of premature
discharge from the military and is related to more than
$130 million in annual excess training costs (see Refs.
[10,11] for review). As of 2006, it was estimated that
tobacco use costs military approximately $564 million
per year from the associated adverse health consequences
(e.g., lower productivity and levels of physical fitness)
and treatment of tobacco-related diseases (see Refs.
[8,11,12] for review).
Cardiovascular disease (CVD), chronic obstructive pul-
monary diseases (COPD), and various forms of cancer are
the leading causes of smoking-related mortality in the
United States [13]. Sustained smoking cessation is associ-
ated with significantly decreased risk for these conditions[13], indicating that several adverse health consequences
related to smoking are modifiable. It is now apparent that
smoking-related morbidity extends beyond CVD, COPD,
stroke, and cancer and includes neurobiological and neuro-
cognitive abnormalities (e.g., hippocampal volume loss,
learning and memory deficits) that are not solely attributable
to the foregoing medical conditions, and some abnormalities
show significant progression over time [14–17]. Importantly,
some of these smoking-related neurobiological abnormal-
ities may represent risk factors for Alzheimer’s disease
(AD) [18–21]. Correspondingly, there is now substantial
epidemiologic evidence from meta-analyses and cohort-
based studies that indicates smoking is associated with a
significantly increased risk for AD neuropathology and asso-
ciated dementia [22–24].
This review will focus on the epidemiologic evidence for
smoking as a risk factor for late-onset/sporadic AD demen-
tia, as well as provide a comprehensive review of the poten-
tial mechanisms by which smoking may promote increased
AD risk. Original and novel data are presented from compar-
isons of cognitively normal elder smokers and nonsmokers
on regional brain b-amyloid (Ab) deposition, via florbetapir
fluorine 18 (F-18) positron emission tomography (PET; see
Section 7). A synopsis is provided following each major sub-
section or section, and an inclusive summary (Section 8) and
conclusions (Section 9) are provided after the review of the
literature and presentation of original data from our group.2. Alzheimer’s disease
AD is the most common cause of dementia, and late-
onset AD (i.e., onset at65 years of age) is the predominant
form (.90% of AD cases) [25,26]. More than 35 million
individuals worldwide are estimated to suffer from AD,
and this number is projected to nearly double by 2030
because of increasing life expectancy [26]. In 2012, an esti-
mated 5.2 million Americans older than 65 years (i.e., one in
eight) had AD, resulting in approximately $200 billion in
health care–related costs [25]. Recent research criteria
recognize that AD is an insidious process, which begins
with extended asymptomatic preclinical stages that may
last for several decades before dementia symptomatology
is exhibited [27]. As the AD-related neuropathologic abnor-
malities accumulate over time during the preclinical stages,
there is a transition from normal neurobiological and neuro-
cognitive function into mild cognitive impairment (MCI),
which is most frequently typified by AD-like neuropa-
thology and clinically significant memory deficits [28,29].
MCI patients are at high risk for conversion to AD, with
50% to 70% converting to dementia within 5 to 7 years
after MCI onset [29]. The increasing incidence of AD has
promoted extensive research into delineating the risk factors
associated with the development and progression of this
neurodegenerative disease [30]. Despite this major multidis-
ciplinary research effort, the mechanisms associated with
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tively established, and both preclinical and human clinical
trials on AD pathology/progression–modifying medications
have yielded disappointing results [27,31].2.1. AD pathophysiology and neuropathology
Two of the hallmark neuropathologic findings in AD are
extracellular amyloid and neuritic plaques and intracellular
neurofibrillary tangles [32]. Amyloid plaques are primarily
formed by aggregation of insoluble Ab peptides, whereas
neuritic plaques are composed of insoluble Ab peptides, de-
generated neurites (dendrites, axons, and/or telodendria),
and some contain hyperphosphorylated tau proteins (p-tau)
[32]. Neurofibrillary pathology (pretangles, neuropil
threads, and neurofibrillary tangles) is primarily composed
of intracellular p-tau protein aggregates [32,33]. Insoluble
argyrophilic neuropil threads and neurofibrillary tangles
develop in the dendrites and cell body, respectively [34]. Ag-
ing and APOE genotype (ε4 . ε3 . ε2) are independently
associated with increased cerebral Ab deposition [35–37]
and may interact where Ab deposition, beginning in the
early 40’s, is greater with increasing age in APOE ε4
carriers [38]. Aging is also related to cerebral p-tau accumu-
lation and neurofibrillary tangle density [34,36,39].
The current predominant hypothesis (although not univer-
sally accepted; for review see Refs. [40–44]) for the
development of AD indicates that pathologic Ab metabolism
is the primary event promoting plaque formation, followed
by widespread cortical tau pathology, inflammation, synaptic
degradation, and neuronal loss (see Refs. [32,40,45] for
review). Brain amyloid deposition is indicated to be
necessary, but not sufficient, to promote the clinical
symptomatology demonstrated in MCI and AD [27]. The
pivotal role of Ab in the development and progression of AD
is supported by the genetic link between hereditary/familial
AD and mutations in either the gene encoding for the amyloid
precursor protein (APP) or in the genes encoding for APP-
processing enzymes (presenilin 1 and 2) [46]. Ab deposition
andplaque formation are indicated to begin as early as 20years
(i.e., during middle age) before the onset of AD symptoms
[46–49]. Cerebral amyloid and neuritic plaque development
follows a predictable pattern of progression, beginning with
diffuse amyloid plaques in the inferior/basal temporal
neocortex, spreading to the hippocampus and entorhinal
cortex, and ultimately, widely distributed amyloid and
neuritic plaques are present throughout the neocortex [34].
InAD, amyloid deposition is not exclusively relegated to brain
parenchyma but can also be found, in variable levels, in lepto-
meningeal and intracortical arteries, arterioles, capillaries, ve-
nules, and veins [50,51]. Significant vascular amyloid
deposition is referred to as cerebral amyloid angiopathy
(CAA) [52] and is primarily composed of the Ab1-40 isoform
[53]. Vasculature in the occipital lobe and cerebellum tends
to show the greatest level of CAA [54].The AD amyloidogenic process begins with the proteol-
ysis of the transmembrane APP. If APP is cleaved by a-sec-
retase, extracellular soluble APPa is produced and Ab
peptide formation is inhibited [55]. In contrast, Ab peptides
are created from the sequential cleavage of APP by b- and g-
secretases; b-secretase initially cleaves APP to yield extra-
cellular soluble APP (sAPPb) and an intracellular carboxyl
terminal fragment (b-CTF), which is subsequently cleaved
by g-secretase, and produces Ab peptides of different
lengths [55,56]. Ab1-40 and Ab1-42 are major isoforms
[57], and these may aggregate to produce dimers, trimers,
oligomers, protofibrils, and insoluble fibrils (which are a
fundamental Ab component of amyloid and neuritic pla-
ques) [58]. Ab1-42 is considered the greater pathologic iso-
form because of its strong association with atrophic
neurites, reactive astrocytosis, and activated microglia
[59]. The redox potential (i.e., ability to acquire electrons)
of the primary Ab species (Ab1-42 .. Ab1-40) is consistent
with their level of neurotoxicity, and redox-active transition
metals (e.g., iron and copper) known to increase reactive ox-
ygen species (ROS) free radical levels bind with high affinity
to all Ab isoforms [60]. It is also established that soluble and
oligomeric intracellular Ab and extracellular neuritic forma-
tion are associated with a chronic neuroinflammatory pro-
cess marked by activated microglia and reactive astrocytes
[61,62]. The insertion of Ab1-42 oligomers into the
phospholipid bilayer serves as a source of oxidative stress
(OxS) via increased concentrations of reactive oxygen and
nitrogen species free radicals, which damage cell membranes
and other micro- and macrocellular components, via lipid
peroxidation [55]. However, it has also been proposed that
some Ab isoforms may serve as antioxidants, and Ab produc-
tion represents a compensatory response tomitigate preexisting
chronic OxS (see Refs. [42,63,64] for review). The level of
soluble Ab oligomers, not amyloid or neuritic plaque load,
shows a stronger association with cognitive decline and p-tau
concentration, in animal models and humans (see Refs.
[55,58] for review).
Neurofibrillary tangles show a different regional pattern
of development and temporal appearance than Ab deposi-
tion and neuritic plaque formation [36]. In AD, neurofibril-
lary tangles first appear in the brainstem and transentorhinal
cortex, spreading to the entorhinal cortex and hippocampus,
and finally showing diffuse distribution throughout the
neocortex [34]. Specifically, neurofibrillary tangles local-
ized in the locus coeruleus and entorhinal cortex are com-
mon in adults aged 30 to 40 years and precedes the
appearance of significant amyloid deposition and neuritic
plaques in these regions [39]. Widespread neurofibrillary
tangles in neocortical regions are typically not prominent
until high amyloid or neuritic plaques levels are present
[32], and medial temporal lobe tangle formation is also inde-
pendently related to age [65]. Currently, there is extensive
debate regarding whether the development and progression
of Ab and tau protein pathologies in AD are interrelated or
represent independent pathophysiological processes [34,66].
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Although the mechanisms responsible for the inception
and progression of late-onset AD are not established,
increasing age and inheritance of the ε4 allele of the
APOE gene are the strongest and most consistently repli-
cated risk factors for the development of AD [25,67,68].
Specifically, the risk for AD doubles every 5 years
between the ages of 60 to 90 years [68], AD risk for those
with one copy of the APOE ε4 allele is increased by three
to five times, and inheritance of two copies (i.e., APOE ε4
homozygotes) is associated with a 12-fold increased risk
[69]. Aging and APOE genotype may interact with other po-
tential genetic and/or modifiable environmental risk factors
to increase AD-related pathophysiology and risk for AD
[38,70–72]. CVD, cerebrovascular disease, moderate-to-
severe traumatic brain injury (TBI), and race may also be
risk factors for AD [25,73]. An increasing number of
investigations have focused on the identification of risk
factors for AD that are “modifiable,” that is, conditions or
behaviors that can be effectively treated/altered to reduce
their prevalence during the asymptomatic preclinical stage
[74], which will promote a significant decrease in the prev-
alence of AD [70]. However, there is considerable debate on
the strength of the association between AD and potentially
modifiable risk factors [67,70].3.1. Modifiable risk factors for AD: Smoking
Cognitive engagement, diet/nutritional supplement intake,
physical activity level, type 2 diabetes, alcohol consumption
level, mood disorders, hypertension, hypercholesterolemia,
and smoking have been proposed as modifiable risk factors
for AD [67,70,75,76]. In 2011, a multidisciplinary panel
convened by the National Institutes of Health reviewed the
cohort studies and randomized controlled trials conducted
from 1984 to 2009 on the foregoing potential risk factors
and concluded “insufficient evidence exists to draw firm
conclusions on the association of any modifiable risk factors
with risk of AD.” [67] However, for smoking, the panel’s
rigorous review criteria resulted the consideration of a very
limited number of studies, and their conclusions were funda-
mentally based on a single meta-analysis [77] of 19 prospec-
tive cohort studies published up to 2005 and two cohort
studies published in 2006 [78] and 2007 [79]. Although the
panel’s conclusions for many of these modifiable risk factors
are likely applicable to the present day, there are substantial
additional data that suggest smoking is a significant risk factor
for AD. Specifically, a conclusive and authoritative meta-
analysis conducted by Cataldo et al. [22] in 2010, on 43 inter-
national case-controlled and cohort studies published from
1984 to 2009, revealed that tobacco industry affiliation
(e.g., study funding provided by the tobacco company, study
author(s) currently/previously employed by tobacco industry)
was robustly related to the direction and magnitude of smok-
ing as a risk factor for AD. In case-controlled studies with atobacco industry affiliation, smoking was associated with a
significantly decreased risk for AD (odds ratio [OR] pooled,
0.86; 95% confidence interval [CI], 0.75–0.98), but studies
with no tobacco industry affiliation showed no association be-
tween smoking and risk forAD.Cohort studieswith a tobacco
industry affiliation demonstrated a significantly decreased
risk for AD (pooled OR, 0.60; 95% CI, 0.27–1.32), whereas
those with no tobacco industry affiliation showed a signifi-
cantly increased risk for AD (pooled OR, 1.45; 95% CI,
1.16–1.80). Some studies in this meta-analysis reported
that the risk for development of AD was greater only in
smokers who were not APOE ε4 carriers [80–83]. After
concurrently controlling for study design, quality (based
on the impact factor of the journal), secular trend, tobacco
industry affiliation, and year of publication, Cataldo et al.
indicated that active and former lifetime smoking was a
significant risk factor for AD (relative risk, 1.72; 95% CI,
1.33–2.12). Although the year of publication was included
as a covariate in their primary analyses, the authors
acknowledge that this variable may be systematically
related to studies reporting a reduction in AD risk for
smokers because all the industry-affiliated/sponsored re-
views were published in 1994 or earlier; this may also be
attributable to the fact that the tobacco industry ceased fund-
ing support for reviews on smoking-related risk for AD af-
ter 1994.
In the nontobacco industry–affiliated cohort studies re-
viewed by Cataldo et al., there were generally consistent
findings for smoking exposure variables (i.e., pack-years, a
measure of cigarette smoking dose and duration) for AD
risk, butmixed results were apparent for former smoking sta-
tus as a risk factor for AD.With respect to exposure, Ott et al.
[80] reported that the risk for ADwas significantly increased
for active smokers with ,20 pack-years (OR, 2.5; 95% CI,
1.1–5.5) and for those with .20 pack-years (OR, 3.0; 95%
CI, 1.2–5.4); a corresponding increased risk for AD was
observed in former smokers with ,20 pack-years (OR,
1.5; 95% CI, 1.0–2.5) and .20 pack-years (OR, 2.1; 95%
CI, 1.2–3.7). In a combined group of active and former
smokers, Tyas et al. [84] found that smokers with 27 to 41
pack-years (OR, 2.55; 95% CI, 1.22–5.58) and 41 to 56
pack-years (OR, 2.92; 95% CI, 1.37–6.53) had a signifi-
cantly greater risk for AD compared with those with ,27
pack-years; however, those with .56 pack-years showed
no statistically significant increased risk for AD (OR, 1.37;
95% CI, 0.53–3.44), which was attributed to a strong survi-
vor bias. Juan et al. [85] in an independent cohort, applied
the same pack-year groupings as Tyas et al. and obtained
highly similar results. Reitz et al. [79] reported that active
smokers with .20 pack-years had a significantly increased
risk for AD than active smokers with ,20 pack-years (haz-
ard ratio, 1.82; 95%CI, 1.26–2.57). Regarding former smok-
ing status, Launer et al. [86] observed an increased risk for
AD in male (relative risk, 1.97; 95% CI, 0.92–4.22) but
not in female (relative risk, 1.08; 95% CI, 0.73–1.61) former
smokers. Merchant et al. [81] and Reitz et al. [79] reported
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different from never smokers, whereas in Aggarwal et al.
[78], former smokers, who were APOE ε4 carriers had a
significantly lower risk for AD relative to never smokers
(OR, 0.27; 95% CI, 0.08–0.93). Notably, greater pack-
years were associated with increased mortality in controls
and AD [84], and the onset of AD occurred at a significantly
younger age in former [80] and active smokers [80,81,87]
compared with never smokers.
Subsequent to the meta-analysis by Cataldo et al., a large
Finnish cohort study [23] reported that individuals who
smoked during midlife and were APOE ε4 carriers demon-
strated a markedly increased risk for AD (OR, 6.56; 95%
CI, 1.80–23.94) [23]. Additionally, a large US cohort study
found individuals who smoked .2 packs/day had a signifi-
cantly increased risk for AD (hazard ratio, 2.57; 95% CI,
1.63–4.03) [24]. Finally, Barnes and Yaffe [70] estimated
the influence of the prevalence of several modifiable AD
risk factors on AD prevalence. Smoking was projected to ac-
count for 574,000 (11%) of AD cases in the United States
and 4.7 million (14%) cases worldwide. A 10% reduction
in the total number of smokers in the United States and
worldwide was projected to decrease the prevalence of AD
cases by 51,000 and 412,000, respectively.
For all the aforementioned case-controlled and cohort
studies, there was considerable variability in the sample
sizes, the duration that participants were followed (for
cohort studies), and the covariates (e.g., APOE genotype,
alcohol consumption, sex, biomedical risk factors) measured
and/or controlled for in statistical analyses. Survivor bias has
been indicated to promote an underestimation of the
smoking-related risk for AD in both case-controlled and
cohort studies [88–92]. Specifically, elders who die
prematurely from smoking-related diseases are a major
source of attrition; this reduces the proportion of smokers
who may have ultimately developed AD, creates attrition
in cohort studies, and those smokers who do survive are
biased toward healthier individuals [92]. The findings
regarding the former smoking status as an AD risk factor
must be interpreted with caution because some studies
were not consistent or explicit about the level of cigarette
consumption or duration of smoking cessation [93]. Addi-
tionally, the association of other forms of tobacco consump-
tion (e.g., pipe, cigars, cigarillos, smokeless tobacco) and
risk for AD was not specifically considered in previous
case-controlled and cohort studies.3.2. Synopsis
The cumulative body of data from international cohort
studies, with no affiliation to the tobacco industry, indicate
that smoking during lifetime is associated with at least a
1.7 times (70%) greater risk for AD, and the risk markedly
increases with greater cumulative cigarette exposure. The
relationship between smoking status, exposure, and AD
risk may be mediated or moderated by APOE genotype.The magnitude of risk for AD associated with smoking is
likely to be underestimated in both case-controlled and
cohort studies because of attrition/survivor bias resulting
from smoking-related mortality and morbidity. Smoking is
associated with earlier onset of AD and estimated to account
for 4.7 million AD cases worldwide.4. Neurocognitive and neurobiological consequences of
smoking
The vast majority of research investigating the effects of
smoking on the human body has focused on the cardiac, pul-
monary functions, and vascular systems, aswell as on its carci-
nogenic properties, primarily in the elderly (i.e.,.65 years of
age) [94–97]. However, outside of cerebrovascular risk factors
for stroke, comparatively little research has been devoted to
effects of chronic smoking on the brain and its functions,
particularly in young/middle-aged adults (i.e., 25–65 years
of age) [14,16]. Over the past 12 years, there has been an
emergence of studies specifically focusing on the
neurocognitive and neurobiological effects of smoking in
multiple populations. The findings from these studies
suggest that smoking is associated with adverse effects on
brain neurobiology and function in those without a history of
clinically significant psychiatric and biomedical conditions,
with a history of a neuropsychiatric disorder (e.g.,
schizophrenia, alcohol/substance use disorder), and with a
history of mild TBI. Smoking is highly prevalent in these
populations in both civilians and US veterans and active
duty military personnel [9,98]. The findings for smokers in
the above populations are highly relevant because the pattern
of neurobiological and neurocognitive abnormalities
observed (see the following) are congruent with many of the
neuropathologic and neurocognitive abnormalities that
characterize the recently proposed “preclinical” stages of
AD [27,49], as well as MCI [99–101]. See the studies by
Sharma and Brody [15] andAzizian et al. [16] for comprehen-
sive reviews on the effects of smoking on neurobiology and
neurocognition in other neuropsychiatric conditions (e.g.,
schizophrenia).4.1. Smoking in “healthy” nonclinical cohorts
Smoking in adolescents to young adults (i.e., 17–21 years
of age), young to middle-aged adults (i.e., 25–60 years of
age), and elders (65 years of age) without a history of clin-
ically significant biomedical or psychiatric conditions is
associated with significant neurocognitive and/or neurobio-
logical abnormalities.
Adolescent to young adult active smokers showed infe-
rior performance relative to never smokers on measures of
attention, learning and memory, processing speed, and im-
pulse control (see Ref. [14] for review).
Young to middle-aged adult active smokers, compared
with never smokers, showed poorer performance onmultiple
neurocognitive domains, predominantly on measures of
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memory [14,102,103]. Young to middle-aged active
smokers also demonstrated abnormalities in regional
cortical, hippocampal, and subcortical morphology (vol-
umes and cortical thickness) [16,19,104–108];
biochemistry (markers of neuronal integrity and cell
membrane turnover/synthesis) [109,110]; white matter
(WM) microstructural integrity [111]; and cortical perfusion
[15]. In these studies, the neurobiological abnormalities
were predominant in anterior brain regions (e.g., orbitofron-
tal cortex, dorsolateral prefrontal cortex, anterior cingulate
cortex, insula), which are cortical components of the brain
reward/executive oversight system that is involved in the
development and persistence of all addictive disorders
[18,112]. The neurobiological abnormalities demonstrated
by young to middle-aged adults were also apparent in re-
gions that show significant atrophy (e.g., hippocampus, pos-
terior cingulate, precuneus) and/or glucose metabolism
deficits in MCI and/or early stage AD [113,114]. In
several studies, pack-years were related to the level of neuro-
biological [104–107] or neurocognitive [14,103]
abnormalities observed.
In the elders, active smokers, relative to never smokers,
demonstrated poorer performance in cross-sectional studies,
and a greater rate of decline in longitudinal studies in the do-
mains of executive functions, processing speed, and learning
and memory (see Ref. [14] for review). Early longitudinal
computer tomography studies of elders reported that active
smokers showed a greater rate of global brain atrophy rela-
tive to never smokers [14]. More recent magnetic resonance
imaging (MRI) studies with elder cohorts reported that
active smokers showed lower gray matter (GM) density in
posterior cingulate gyrus and precuneus bilaterally, right
thalamus, and right precentral gyrus [21], and those with
any history of smoking demonstrated a greater rate of atro-
phy over 2 years in anterior frontal, temporal, posterior
cingulate, and posterior parietal regions. Primarily in elders,
former smokers demonstrated neurocognitive and neurobio-
logical abnormalities that were intermediate to active and
never smokers [14].4.2. Smoking in alcohol use disorders
Smoking is the most prevalent comorbid condition in
those with an alcohol use disorder (AUD) [98]. For the
past 10 years, we have applied multimodality magnetic reso-
nance neuroimaging methods and comprehensive neurocog-
nitive assessment to investigate the effects of smoking and
hazardous alcohol consumption on the brain and its func-
tions in young to elderly adults (25–69 years of age) seeking
treatment for AUDs (trsAUD). Most of our trsAUD partici-
pants are US Armed Services veterans. At 1 to 4 weeks of
abstinence from alcohol, smoking trsAUD consistently
demonstrated significantly greater abnormalities than
nonsmoking trsAUD on magnetic resonance–derived mea-
sures of brain structure, neuronal integrity, and perfusion,primarily in the frontal and temporal lobes (including the
hippocampus), as well as poorer performance on measures
of learning and memory, cognitive efficiency, executive
functions, processing speed, and fine motor skills
[112,115–120]. Smoking trsAUD also showed significantly
less recovery than nonsmoking trsAUD in brain metabolite
markers of neuronal integrity and cell membrane turnover/
synthesis in the frontal and medial temporal lobes, frontal
GM perfusion and microstructural integrity in the frontal,
temporal, and parietal WM, as well as in neurocognition,
over 1 month of abstinence [121–123], and multiple
domains of neurocognition over 1 month [124] and 9 to
12 months of abstinence [125]. Recently, we also observed
that smoking trsAUD relative to nonsmoking trsAUD had
thinner cortex and lower N-acetylaspartate levels (marker
of neuronal integrity), in anterior frontal and temporal re-
gions at entry into treatment [126]. Recent analyses also
indicated that smoking trsAUD showed greater age-related
volume loss than nonsmoking trsAUD in the anterior frontal
regions and the insula, as well as poorer performance with
increasing age on measures of learning and memory, cogni-
tive efficiency, executive functions, processing speed, and
fine motor skills at 1 month of abstinence [105,127]. In
several of our studies, greater smoking exposure (i.e.,
lifetime years of smoking or pack-years) was related to
greater neurobiological and/or neurocognitive abnormalities
in cross-sectional studies or poorer recovery in longitudinal
studies [105,115–117,122,125,127,128]. The level of
nicotine dependence in these studies showed weak or no
association with neurobiological and neurocognitive
measures.
4.3. Smoking in mild TBI
In those with a mild TBI, we observed that active smokers
demonstrated significantly poorer recovery than never
smokers over 6 months post injury on measures of process-
ing speed, visuospatial learning and memory, visuospatial
skills, and global neurocognition. Similar to AUD cohorts,
greater smoking exposure (i.e., lifetime years of smoking
or pack-years) was robustly related to less improvement on
measures of visuospatial learning, visuospatial memory,
working memory, visuospatial skills, and global cognition
[129].
4.4. Synopsis
Smoking in nonclinical and clinical populations is
strongly related to multiple neurocognitive and neurobiolog-
ical abnormalities. Many of the neurocognitive (e.g.,
learning and memory, executive function, processing speed
deficits) and neurobiological (e.g., hippocampal and lateral
temporal volume loss, regional cortical thinning, and
decreased markers of neuronal integrity) abnormalities
demonstrated by nonclinical smokers and smokers with
AUD are pathognomonic markers of preclinical stages of
AD and MCI. The progressive regional atrophy and
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sent as risk factors for the transition from MCI to AD
[18,20,29,30]. The neurobiological and neurocognitive
abnormalities observed in late adolescents through middle-
aged adult smokers are highly relevant for the US Armed
Services, given that most of active duty personnel are be-
tween the ages of 18 and 50 years, and the higher prevalence
of smoking compared to civilians in the corresponding age
range [9]. The neurobiological and neurocognitive sequelae
associated with mild TBI and AUD/hazardous alcohol con-
sumption may be exacerbated by smoking, and impaired re-
covery from these conditions is associated with smoking.
These findings are of considerable import to all branches
of the military because personnel engaged in combat opera-
tions are at a significantly increased risk for mild TBI and
AUD/hazardous alcohol consumption [130,131].
A primary pathophysiological mechanism that is hypoth-
esized to contribute to the neurobiological and neurocogni-
tive abnormalities observed in smokers is cerebral OxS
[14,17]. Correspondingly, OxS may serve as a factor
promoting the greater risk for AD observed in smokers,
which is addressed in the following section.
5. Smoking-related neuropathology: The role of OxS
5.1. Oxidative stress
OxS is indicated by the detection of damage to brain and
other organ system tissues that is caused by ROS, or more
broadly by damage from ROS, reactive nitrogen species
(RNS), and other oxidizing agents [60,63,132]. Increased
levels of free radical species (i.e., ROS and RNS) and
oxidants result from an imbalance between the generation
of these compounds via endogenous (i.e., normal cell
metabolism) and/or exogenous sources (e.g., smoking) and
their chemical reduction by antioxidants/radical scavengers
[60,133,134]. Irrespective of the source, increased free
radical concentrations are directly associated with oxidative
damage to membrane lipids, proteins, carbohydrates, DNA,
and RNA of neuronal, glial, and vascular brain tissue
[133,135–141].
Cytokines, which include chemokines, interferons
(IFNs), interleukins (ILs), growth factors, and tissue necro-
sis factors (TNFs), are a major component of a highly com-
plex system that controls immune and inflammatory
responses in the peripheral nervous system and central ner-
vous system (CNS) [142]. Oxidative damage from free
radical or other oxidants may trigger inflammation via a
cytokine-mediated immune response [143] that involves
release of anti-inflammatory and proinflammatory cytokines
(e.g., TNFa, IL-1, IL-6) by peripheral and CNS cells (e.g.,
microglia and astrocytes) [142]. Elevated proinflammatory
cytokine levels are associated with cerebral OxS and
apoptosis through generation of ROS and other inflamma-
tory mediators in the brain (and peripheral organ systems)
by immune cells, microglia, and astrocytes [142,144,145].
Therefore, OxS and inflammation often occur in tandem inmany diseases/disorders, including AD, smoking,
substance use disorders, and AUDs [14,55,62,146–149].
The brain is highly susceptible to OxS caused by free rad-
icals and other oxidizing agents because of its high meta-
bolism and energy demand and vulnerability of membrane
phospholipids to peroxidation by radical species [150–154].
The anterior frontal lobe, medial and lateral temporal lobe
[155,156], and hippocampus are particularly vulnerable to
OxS-mediated cellular damage [60]. See Refs.
[143,148,157,158] for details on OxS-mediated cell damage,
apoptosis, and neurodegeneration. Smoking-induced OxS,
via increased ROS and RNS levels, is also robustly related
to an increased risk for atherosclerosis, chronic obstructive
pulmonary disease, and carcinogenesis in humans
[132,133,141,159–163].5.2. Cigarette smoke/combustion products, nicotine, and
OxS
Cigarette smoke is a complex admixture of approxi-
mately 5000 combustion products (including nicotine),
which contain a high number of cytotoxic and carcinogenic
compounds [164]. The gas and particulate phases of ciga-
rette smoke have extremely high concentrations of short-
and long-lived ROS, RNS, and other oxidizing agents
[94,133]. In addition to increased free radical
concentrations, smoking is associated with markedly
elevated carboxyhemoglobin levels [165], altered mitochon-
drial respiratory chain function [166], and induction of
proinflammatory cytokine release by peripheral and CNS
glial cells [167], which collectively promote significant ce-
rebral OxS.
5.2.1. In vitro and animal studies
Giunta et al. [168] demonstrated that in vitro exposure
of microglia (BV-2) to cigarette smoke condensate pro-
moted significantly increased release of TNF-a and IL-
1B proinflammatory cytokines. Barr et al. [169] reported
that nicotine administration to rat mesencephalic cells in-
ducted high ROS levels and activated nuclear factor kappa
B (NF-KB) (involved in inflammation, innate immunity,
development, apoptosis, and antiapoptosis). In a series
of studies by Anbarasi et al., rats were exposed to daily
cigarette smoke for 12 weeks. Homogenized brain tissue
showed consistent evidence of OxS (i.e., lipid peroxida-
tion [170], increased creatine kinase [171], and increased
apoptotic markers [172]), as well as OxS and dysfunction
specifically in mitochondria (i.e., lipid peroxidation,
diminished oxidative phosphorylation) [173]. Rueff-
Barroso et al. [174] reported that mice exposed to daily
cigarette smoke for 15 weeks demonstrated significant
OxS in homogenized whole brain tissue as indicated by
an elevated malondialdehyde level, a marker of lipid per-
oxidation. Ho et al. [175] found that rats exposed to daily
cigarette smoke for approximately 8 weeks showed signif-
icantly increased levels of 8-hydroxyguanine, a marker of
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dentate and CA3 subfields of the hippocampus [175].
Khanna et al. [147] reported that rats exposed to cigarette
smoke 5 d/wk for 6 weeks exhibited significantly
increased brain IFN-g and TNF-a proinflammatory cyto-
kine levels, as well as upregulation of the expression of
multiple cytokine genes (e.g., TNF-a, IL1-a, IL1-b,
Th17). Das et al. [176] observed that rats treated with
intraperitoneal nicotine for 7 days showed significant lipid
peroxidation and protein oxidation in mitochondria from
cortical, diencephalic, and cerebellar tissue.
5.2.2. Human studies
Sonnen et al. [177] conducted postmortem comparisons
of human smokers and never smokers (87 6 6 years of
age) without significant AD or microvascular pathology.
Active smokers showed significantly higher cortical F4-
neuroprostanes, a measure of neuronal free radical–medi-
ated lipid peroxidation, but groups were not different on
measures of cerebellar lipid peroxidation. Additionally,
numerous human studies have shown elevated markers
of OxS (e.g., F2-isoprostanes, hydroxycholesterols, C-
reactive protein) in the serum or plasma of smokers
[132,178–184].5.3. Cigarette smoke/combustion products and
antioxidant depletion
The combined activity of enzyme-based (e.g., superoxide
dismutase, catalase, glutathione reductase) and non–
enzyme-based (e.g., glutathione and vitamins A, C, and E)
antioxidants and radical scavengers is responsible for man-
aging the levels of free radicals and other oxidants in the
brain [151,185]. Acute exposure to radical species and
oxidizing agents promotes an adaptive increase in the
production of enzyme-based antioxidants to mitigate oxida-
tive damage [151]. Deficiencies in the production and/or
maintenance of optimal levels of these antioxidant com-
pounds can result in significantly increased radical and
oxidant concentrations (via endogenous and/or exogenous
sources), which promote OxS [151,157,158,186,187].
Glutathione is the dominant antioxidant in the human brain
with regional concentrations from 0.8 to 5.0 mM [188–
190], and oxidized forms represent ,1% of the total
glutathione level [191]. Glutathione is critically involved in
the chemical reduction of ROS and hydrogen peroxide and
in maintenance of other antioxidants (e.g., vitamins A, C,
and E) in their chemically reduced functional forms
[135,153,191–193]. Decreased central and peripheral
glutathione concentrations is a longstanding and accepted
proxy for OxS [134,153,186,187,193–195].
5.3.1. Animal studies
In vivo chronic cigarette smoke exposure to rats was asso-
ciated with significantly decreased enzyme-based free radical
and non–enzyme-based radical scavenger concentrations inbrain homogenates [151,196]. Chronic cigarette smoke
exposure was specifically associated with a significantly
decreased glutathione level in rodent brains [151,170,197].
Das et al. [176] reported that intraperitoneal nicotine admin-
istration over 7 days in rats, along with OxS (see Section
5.2.1), significantly decreased multiple enzyme-based radical
scavenger levels in brain mitochondria.
5.3.2. Human studies
In humans, smoking was related to significantly reduced
glutathione level in plasma/serum across race and sex
[64,135,178,179,181,197–199], as well as decreased serum
superoxide dismutase and vitamin C [178,179]. Smoking
was also shown to directly decrease glutathione production
via alterations of its synthetic pathway [135,181], and
dietary differences did not account for reduced glutathione
levels [178,198]. The decreased glutathione and other
antioxidant concentrations in smokers are postulated to
result from the amplified demand to detoxify (i.e.,
chemically reduce) the chronically high ROS and RNS
levels delivered in cigarette smoke [151,178,198,200].
5.4. OxS, amyloidogenic pathway, and tau
phosphorylation
Ab isoforms are indicated to promote OxS in brain tis-
sue and AD-related disease progression (see Section 2.1)
[55]. However, cerebral OxS has also been hypothesized
to be involved in the initiation of AD pathophysiological
process, rather than strictly emerging as a physiological
consequence of existing amyloid- or tau-based neuropa-
thology [63,201–203]. More specifically, in vitro studies
of various brain cell types reported that OxS induced by
exogenous agents (e.g., hydrogen peroxide) is associated
with increased b-secretase cleavage of APP, under mild
and toxic OxS conditions, and amplified OxS does not
increase b-secretase levels in cells lacking presenilins or
APP [204,205]. Additionally, in vitro and in vivo
preclinical models have demonstrated that OxS promotes
abnormal tau phosphorylation in the brain (see Refs.
[42,149,203] for review). Therefore, smoking-related
OxS may serve as a fundamental mechanism contributing
to the neurobiological abnormalities (e.g., brain atrophy,
regional cortical thinning) observed in smokers in clinical
and nonclinical cohorts [14,17], as well as for an
increased risk for development of Ab and tau pathology
[63,79,84,168,175,206,207].
5.5. Synopsis
The in vitro and animal studies and literature clearly
demonstrate a causal relationship between in vivo chronic
cigarette smoke/condensate and nicotine exposure and cere-
bral OxS; cigarette smoke/condensate, nicotine, and
increased proinflammatory cytokines (via activation of im-
mune cells, microglia, and astrocytes) promote high concen-
trations of ROS, RNS, and other oxidants. Animal models
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causally linked to significant cerebral antioxidant depletion.
The factors promoting cerebral OxS and antioxidant deple-
tion in animal models are hypothesized to be operational,
in vivo, in the human brain [132,151,168,177], and
evidence of free radical–mediated damage was
demonstrated postmortem in the human brain [177]. Taken
together, existing literature indicates that smoking and
pure nicotine (1) promotes high concentrations of ROS,
RNS, and other oxidizing compounds; (2) upregulates activ-
ity and release of proinflammatory cytokines in the brain,
which promotes immune system–mediated discharge of
additional free radicals and oxidizing compounds; and (3)
depletes enzyme- and non–enzyme-based antioxidants sec-
ondary to increased demand for the chemical reduction of
high radical concentrations (from cigarette smoke and proin-
flammatory cytokine signaling) and inhibits the production
of glutathione, the primary antioxidant in the human brain.
The combination of these conditions serves to place the
brain and other organ systems of smokers under a state of
chronic OxS. Importantly, OxS is associated with increased
b-secretase cleavage of APP as well as tau phosphorylation;
therefore, smoking-related OxS may serve as a fundamental
mechanism initiating the AD pathophysiological process.6. Smoking and nicotine: Relationships to AD
pathophysiology
As summarized in Section 5, cerebral OxS has been
implicated in the initiation of AD neuropathology, rather
than strictly developing as a physiological consequence
of existing and/or progressing amyloid- or tau-based path-
ophysiology [42,63,201,202]. Smoking is strongly
associated with cerebral OxS (see Section 5), and OxS
promotes increased b-secretase cleavage of APP and
abnormal tau phosphorylation. Thus, smoking-related
OxS may directly facilitate the amyloidogenic pathway
involved in Ab oligomer production and extracellular
fibrillar Ab aggregation [168], as well as abnormal tau
phosphorylation, which is the basis of neurofibrillary
tangle pathology.
Nicotine is a main constituent of the particulate phase of
cigarette smoke and is principally responsible for promot-
ing physiological dependence on all forms of tobacco
[208]. Nicotine consumption has been suggested to be pro-
tective against AD neuropathology via activation of nico-
tinic acetylcholine receptors (nAChRs) [209,210]. Both
smoking and pure nicotine significantly upregulate the
number of inotropic a4b2 and a7 nAChR subtypes, but
the sensitivity of these receptors is diminished [211,212].
Nicotine binding at nAChRs influences neurotransmitter
release, signal transduction, gene transcription, and cell
survival, apoptosis, and plasticity; a7 nAChRs appear to
be centrally involved in survival, apoptotic, and plastic
mechanisms [212,213]. A significant loss of neurons
and/or synapses expressing nAChRs is apparent in earlyAD, and Ab aggregation is frequently pronounced at
nAChRs [214]. In this section, we first review the link be-
tween smoking/cigarette smoke exposure and AD patho-
physiology; we then review the data on the relationship
between pure nicotine exposure and AD pathophysiology.6.1. Smoking, smoke exposure, and AD pathophysiology6.1.1. In vitro and animal studies
In vitro studies by Giunta et al. [168] showed that ciga-
rette smoke condensate (i.e., the particulate component of
tobacco smoke) increased Ab1-40 and Ab1-42 levels in a
concentration-dependent manner in cells transfected with
human APP (SweAPP N2a cells). In addition to elevated
markers of OxS (see Section 5.2.1) in cigarette smoke–
exposed rats, Ho et al. [175] reported that these rats concur-
rently demonstrated significantly increased b-sAPP, but not
a-sAPP, levels in homogenized hippocampal tissue and
markedly increased Ab accumulation in the CA3 and den-
tate subfields of the hippocampus. The smoke-exposed rats
also showed significantly increased hippocampal p-tau but
not total tau levels. Moreno-Gonzalez et al. [207] exposed
3-month-old APP/presenilin 1(PS1) transgenic mice to
high- (one cigarette over 60 minutes) or low-dosage (half
of a cigarette over 30 minutes) cigarette smoke 5 d/wk for
4 months. The high-dosage group showed levels of cotinine,
the primary metabolite of nicotine, that were physiologically
consistent with human smokers. Both high- and low-dosage
groups begin to develop neuritic plaques at 5 to 6 months of
age. The high-dosage group demonstrated a significantly
greater number of Ab deposits and fibrillar neuritic plaques,
increased density of activated microglia and reactive astro-
cytes, and positive p-tau staining in the majority of the cere-
bral cortex and hippocampus relative to the low-dosage
group and controls.
6.1.2. Postmortem human studies
In a large human autopsy sample, Tyas et al. [84]
observed across elder dementia and nondementia groups
that active and former smokers demonstrated significantly
higher neuritic plaque burden in the cerebral cortex and hip-
pocampus than never smokers, but no differences were
apparent between groups on cortical or hippocampal neuro-
fibrillary tangle count. Furthermore, the risk for Consortium
to Establish a Registry for Alzheimer’s Disease neuropatho-
logically defined AD was more than double for active (OR,
2.64; 95% CI, 0.54–12.88) and former (OR, 2.62; 95% CI,
0.80–11.57) smokers relative to never smokers. Conversely,
in a hospital-based autopsy sample, Ulrich et al. [215]
observed that female never/former smokers, relative to
active smokers, had a lower average density of neuritic pla-
ques in a composite of the hippocampus, entorhinal cortex,
and neocortex, but showed a trend for a higher density of
neurofibrillary tangles. There were no differences between
male smokers and nonsmokers in plaque or neurofibrillary
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were significantly correlated with greater neurofibrillary
tangle density but not with neuritic plaque density.
Sabbagh et al. [87] found no differences in neuritic plaques
or neurofibrillary tangle density in the midfrontal cortex (the
only region examined) between never, former, and active
smokers with AD. Hellstrom-Lindahl et al. [209] observed
that soluble and insoluble Ab1-40 and Ab1-42 levels were
significantly lower in homogenates of the frontal and tempo-
ral cortex, but not the hippocampus, in cognitively normal
active smokers compared with never smokers. In the same
study, active smoker AD cases had lower insoluble and sol-
uble Ab1-40 and Ab1-42 in the frontal cortex than never
smoker AD, but in the temporal cortex and hippocampus,
only insoluble and soluble Ab1-40 levels were significantly
lower in active smoker AD. Perry et al. [216] reported that
nondemented elders who had smoked within 10 years of
(smokers) death had a lower mean neuritic plaque level in
the hippocampus, entorhinal cortex, and neocortex than
those who had quit smoking more than 10 years before death
(nonsmokers); a never smoker group was not available for
comparison. No group differences were observed for neuro-
fibrillary tangles in any region, and APOE genotype did not
mediate the finding for neuritic plaque or neurofibrillary
tangle burden in group comparisons on smoking status; how-
ever, irrespective of the smoking status, APOE ε4 carriers
had lower mean neocortical neuritic plaque density than
noncarriers, which appeared to be driven by the low density
in the small number of smokerAPOE ε4 carriers (n5 4). In a
subsequent study by the same laboratory, Court et al. [217]
found that nondemented elders who smoked most of their
lives/smoked within 15 years of death showed lower entorhi-
nal cortex levels of total and diffuse Ab deposits and insol-
uble Ab1-42 relative to elders who never smoked/quit
smoking at least 25 years before death Higher pack-years
were related to lower entorhinal cortex soluble Ab1-42 level
Groups did not differ on p-tau density.
6.1.3. Synopsis
The in vitro and animal studies showed cigarette smoke
condensate and cigarette smoke exposure consistently
facilitated the amyloidogenic pathway, as well as causally
increased tau hyperphosphorylation. Specifically, chronic
cigarette smoke exposure in normal and AD model trans-
genic animals was causally related to significantly
increased sAPPb level, Ab deposition, and neuritic plaque
burden, as well as increased p-tau levels in the cerebral cor-
tex and hippocampus. Cigarette smoke condensate expo-
sure to cells transfected with human APP produced
increased Ab1-40 and Ab1-42 levels in a concentration-
dependent manner. Markers of increased OxS were con-
currently observed in several of studies demonstrating
amyloidogenic pathway facilitation and tau accumulation.
In contrast, human autopsy studies yielded mixed findings
regarding the association between smoking and AD neuro-
pathology. The interpretation of these human studies isobfuscated by inconsistencies in the assignment of smok-
ing status (e.g., never smokers and former smokers with
variable lengths of smoking cessation combined into a sin-
gle group), small sample sizes in some studies, inconsistent
consideration of potential sex effects, and survivor bias. In
the large-sample study [84] with clear assignment of never/
former/active smokers, significantly greater brain Ab-
related neuropathology was observed in active and former
smokers compared with never smokers. Conversely, in
small sample–sized studies comparing groups of non-
smokers (e.g., combined never and long-term abstinent
former smoker) and smokers (combined active or smoked
within 15 years of death), smokers showed significantly
lower levels of Ab-related neuropathology. One of the
studies [216] reporting smokers showed lower neuritic pla-
que density reported that irrespective of the smoking status,
APOE ε4 carriers had lower mean neocortical neuritic pla-
que density than noncarriers, which is contrary to typically
observed effect of APOE ε4 genotype on plaque density in
humans [68]. Despite the methodological limitations and
inconsistent results across the human postmortem studies,
these findings, combined with the animal and in vitro
data suggest (1) at a minimum, smoking is not protective
of AD-related pathophysiological processes, and smoking
may facilitate the development of regional Ab and tau
pathology and (2) increased OxS is a robust candidate
mechanism contributing to the initiation of the AD patho-
physiological process in smokers.
6.2. Nicotine, nAChR agonists and antagonists, and AD
pathophysiology
6.2.1. In vitro and animal studies
Hellstrom-Lindahl et al. [218] reported that nicotine or
epibatidine (a nonselective nAChR agonist) treatment of
the human neuroblastoma cells (SH-SY5Y) caused
increased levels of p-tau and total tau. Additionally, nico-
tine, epibatidine, or Ab1-42 (as a ligand for nAChRs)
administration induced tau phosphorylation in neuroblas-
toma cells (SK-N-MC) and in hippocampal synaptosomes.
In rats, subcutaneous nicotine administration over 2 weeks
decreased soluble APP peptides [219,220] but increased
levels of total sAPP in the cerebrospinal fluid (CSF)
[220]. Over 6 weeks, rats administered intraventricular
Ab1-40 and Ab1-42 with concurrent subcutaneous nicotine
showed lower levels of Ab1-40 and b-secretase in the hippo-
campal CA1 subfield, better memory, and greater hippo-
campal long-term potentiation compared with rats
administered Ab1-40 and Ab1-42 alone [221]. In transgenic
mice (expressing Swedish human APP), those administered
nicotine in drinking water showed a significant reduction of
neuritic plaques and insoluble Ab1-40 and Ab1-42 levels, but
no changes in soluble Ab1-40 and Ab1-42 levels, in the ce-
rebral cortex, compared with sucrose-treated mice [210].
Transgenic mice (expressing human Ab precursor protein
and PS1 genes) that were administered cotinine, the
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3.5 months, showed lower insoluble Ab1-42 in the cortex
and Ab1-40 in the hippocampus than control transgenic
mice; no differences between treated and control animals
were observed for soluble Ab1-42 and Ab1-40 levels in the
cortex or hippocampus; decreased Ab1-42 oligomerization
was also observed in vitro [222]. Conversely, a study using
transgenic mice (3xTg-AD; expressing combination of
Swedish human APP and tauP30IL) that were administered
nicotine in drinking water for 5 months showed no increase
in soluble or insoluble Ab1-42 and Ab1-40 levels in the hip-
pocampus compared with control transgenic mice; howev-
er, the nicotine-treated mice exhibited a significant increase
of hippocampal tau phosphorylation and aggregation; the
increased hippocampal tau aggregation and phosphoryla-
tion were related to an age-dependent decreased density
of a7 nAChRs in both the nicotine-treated and untreated
mice [223]. Additionally, in vitro exposure of mature
mouse brain mitochondria to nicotine produced no increase
in free radical concentration or corresponding evidence of
lipid peroxidation [224].
6.2.2. Postmortem human study
In a human autopsy study, the effect of several nAChRs
agonists (but not nicotine) and antagonists on 11C Pittsburgh
compound B binding (PiB; shows high affinity binding to
fibrillar Ab [225]) was evaluated in frontal lobe homoge-
nates of elder controls and AD. The smoking status of AD
and control cases was not provided. The a7 nAChR agonists
varenicline and JN403, but not the a4b2 nAChR agonist cy-
tisine, increased PiB binding in both AD and controls. This
effect was abolished by the a7 nAChR antagonists a-bungar-
otoxin, mecamylamine, and methyllycaconitine, but not by
the a4b2 antagonist dihydro-b-erythroidine. Increased PIB
binding promoted by varenicline and JN403 was signifi-
cantly inhibited by preincubation with the amyloid ligand,
BF-227. The acetylcholinesterase inhibitor and allosteric
nAChR modulator galantamine and the N-methyl-D-aspar-
tate receptor blocker memantine did not significantly influ-
ence PiB-binding levels in AD cases [226].
6.2.3. Synopsis
The rodent studies on the effect of chronic nicotine
administration on Ab isoform concentrations and deposition
yielded inconsistent results; nicotine administration in trans-
genic and nontransgenic animals produced significant reduc-
tions of neuritic plaques and insoluble Ab1-40 and Ab1-42
levels in brain tissue, or nicotine caused no increase in solu-
ble or insoluble Ab1-42 and Ab1-40 levels. Regardless of the
use of different species and genetic modifications, variable
routes of nicotine administration, and different assay and
quantitation methods in rodent studies, nicotine did not alter
soluble Ab1-40 and Ab1-42 concentrations in the cortex or
hippocampus. This finding is relevant to humans because
soluble Ab oligomer levels, but not fibrillar Ab-containing
compounds, show consistent associations with cognitivedecline and tau hyperphosphorylation [55]. In humans, a7
nAChR agonists, but not a4b2 nAChR agonists, increased
PiB binding in postmortem frontal lobe homogenates of
elder controls and AD. Additionally, chronic nicotine
administration to adolescent rats evoked cell damage and
loss throughout the brain and with selectively greater effects
in the female hippocampus [227,228]. The interpretation of
the effects of nicotine on Ab-related neuropathology in
animals and humans is further complicated by the
following: (1) AD is associated with a significant
reduction in acetylcholinergic neurons, synapses, and
nAChR expression; (2) active smoking/nicotine
consumption is associated with increased nAChR levels;
(3) neuritic plaque and Ab accumulation show strong co-
localization at nAChRs [229]; (4) APOE ε4 carriers with car-
riers with AD may possess fewer nAChR binding regions
[80]. Therefore, it is clear that the interplay between nico-
tine/cholinergic agonists at nAChRs, particularly a7
nAChRs, and Ab deposition is complex and incompletely
understood [6,226,229]. In contrast to Ab, animal and
in vitro models showed that administration of nicotine and
nAChR agonists consistently induced tau aggregation and
hyperphosphorylation. Overall, the findings across animal
and human studies do not provide consistent evidence that
nicotine and other a7 nAChR agonists are protective
against Ab production and deposition. Notably, preclinical
data indicated that nicotine and nAChR agonists reliably
produced tau hyperphosphorylation. Given in vitro and in
vivo nicotine exposure induces cerebral OxS, and OxS
promotes abnormal tau phosphorylation, the associations
observed between nicotine exposure and increased tau
phosphorylation may be explained by nicotine-inducted
OxS.7. Comparison of elders with and without a history of
smoking on cerebral Ab deposition: Florbetapir PET
7.1. Background and subjects
To our knowledge, there are no published in vivo human
studies that specifically investigated the influence of smok-
ing status on neuroimaging markers of Ab deposition in
cognitively normal elders. Accordingly, we compared a
large cross-sectional sample of cognitively normal elder
control participants from the Alzheimer’s Disease Neuroi-
maging Initiative who were never smokers (n 5 154;
75 6 7 years of age; 17 6 3 years of education) with those
with at least 1 year of smoking during lifetime (smokers;
n 5 109; 76 6 5 years of age; 16 6 3 years of education;
pack-years 5 26 6 21), on cortical Ab deposition, via flor-
betapir F-18 PET. Twelve smokers (11%) were active
smokers at the time of study; former smokers (n 5 97)
quit smoking 34 6 15 years (minimum 5 1 year,
maximum 5 34 years; median 5 37 years) before study.
Smokers (former and current smokers combined) and never
smokers were equivalent on age, education, allowed current
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APOE ε4 carriers, antihypertensive, statins and cholesterol
absorption blockers, and COPD medication use. Smokers
and nonsmokers did not differ on plasma triglyceride and
cholesterol levels, the modified Hachinski score (measure
of cerebrovascular risk factors), or WM hypointensity vol-
ume based on T1-weighted MRI. Smokers had a signifi-
cantly higher frequency of history of alcohol misuse
(P , .05), which is consistent with findings from middle-
aged cohorts [14].7.2. Florbetapir F-18 PET and statistical analyses
Florbetapir shows high affinity and specific binding to
fibrillar Ab deposits in neuritic plaques [230] and is
strongly correlated with the level of neuritic plaque binding
demonstrated by PiB [231]. Mean florbetapir retention was
calculated for prefrontal, anterior/posterior cingulate,
lateral parietal, and lateral temporal GM, and each region
was standardized to whole cerebellar retention. A compos-
ite measure was calculated by taking the average of the four
cortical regions (see adni.loni.usc.edu/research/
pet-analysis/ for details on formation florbetapir quantita-
tion and formation of GM regions of interest). Human
fibrillar Ab deposition, as measured by PET ligands, is
highly related to age, beginning in the fifth decade of life
and suggested to follow a sigmoid curve through old age
[30]. APOE genotype is also strongly related to fibrillar
Ab deposition, with APOE ε4 carriers typically showing
greater deposition than noncarriers, particularly with
increasing age [38,232]. Because a history of smoking in
cognitively normal elders is associated with greater
regional brain atrophy and other neurobiological
abnormalities in the anterior and posterior cingulate and
anterior frontal and posterior parietal and lateral temporal
lobes (see Section 4.3), we predicted that smokers would
demonstrate greater florbetapir retention than nonsmokers
across these regions. A composite GM florbetapir
retention value of 1.11 is designated as an “amyloid-
positive” cutoff, based on levels demonstrated by
individuals who completed a florbetapir PET scan within
12 months of death that showed probable AD at autopsy
(see adni.loni.usc.edu/research/pet-analysis/). We predicted
that a greater percentage of smokers have 1.11 composite
GM retention values. Multivariate analysis of covariance
(MANCOVA) tested for differences between smokers and
never smokers in prefrontal, anterior/posterior cingulate,
lateral parietal, and lateral temporal GM and composite
florbetapir retention, controlling for APOE ε4 carrier status,
age, sex, education, and history of alcohol misuse. Effect
sizes for mean differences between smokers and
nonsmokers on regional florbetapir uptake were calculated
with Cohen’s d. The small number of active smokers
(n 5 12) had numerically higher florbetapir uptake in all
regions than former smokers (data not shown), but these
differences were not statistically significant, so active andformer smokers were combined into one group. The
proportion of smokers and never smokers that were 1.11
versus ,1.11 for composite GM florbetapir was compared
with chi-square. Associations between smoking exposure var-
iables (i.e., pack-years, years of smoking cessation) and
regional florbetapir uptake were examined with partial corre-
lations controlling for age, sex, and APOE ε4 carrier status.
7.3. Results
MANCOVA yielded a significant omnibus effect for
smoking status (active/former smoker vs. never smoker)
[F(5, 252) 5 2.75, P 5 .019]. There were no significant in-
teractions among smoking status and covariates. Follow-up t
tests (two-tailed, P  .025 considered statistically signifi-
cant) indicated that smokers showed greater florbetapir
retention than never smokers in the cingulate, temporal, pa-
rietal, and composite GM (all P , .018; see Fig. 1), with a
trend for the frontal GM (P 5 .065). A significantly higher
proportion of smokers (44 of 109; 40%) than never smokers
(39 of 154; 25%) had florbetapir retention values 1.11 for
the composite GM (two-tailed c25 6.69; P5 .01). Virtually
identical results were obtained for the aforementioned ana-
lyses when only former smokers (n 5 97) were compared
with never smokers. In smokers, there were no significant
associations between cigarette exposure variables (i.e.,
pack-years, lifetime years of smoking, years of smoking
cessation) and florbetapir retention in any region.
7.4. Discussion
The significantly higher regional florbetapir retention in
this large sample of cognitively normal elders with a his-
tory of smoking indicated that they had greater fibrillar
Ab deposition in the cingulate, temporal, parietal, and
composite cortical GM. The greater in vivo florbetapir
retention in these cognitively normal elder smokers is
novel and congruent with in vitro, animal, and human post-
mortem studies that reported cigarette smoke exposure/
smoking was associated with significantly increased Ab-
based neuropathology (see Section 5.2). A significantly
higher proportion of smokers (40%) than never smokers
(25%) had composite GM retention values that fell into
the range demonstrated by those with histologically
confirmed AD. Human postmortem studies have reported
that approximately 30% of cognitively intact elders exhibit
levels of amyloid deposition observed in AD cases
[48,233]. This suggests that the proportion of smokers in
this cohort who demonstrated elevated amyloid
deposition is 10% beyond that expected in the general
population of cognitively normal elders.
Additionally, research criteria [27] have been recently
proposed to stage and operationalize the severity of the
neuropathologic correlates of preclinical AD in cognitively
normal individuals; the stages are as follows: no indications
of elevated amyloid and neuronal injury biomarkers or “sub-
tle” cognitive decline (stage 0), elevated amyloid biomarkers
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Fig. 1. Regional florbetapir retention for smokers and never smokers. Retention values for each region represent the ratio formed by standardization to whole
cerebellar florbetapir retention. Bars represent the group mean and error bars are the standard error of the mean; ES, Cohen’s d effect size; GM, gray matter.
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markers (stage 2), and elevated amyloid, neuronal injury
biomarkers, and subtle cognitive decline (stage 3). Based
on the florbetapir findings alone, approximately 33% of
the entire cognitively normal elder cohort would have been
classified as stage 1 preclinical AD; however, when the
smoking status was considered, 40% of smokers versus
25% of never smokers would be classified as stage 1, after
controlling for APOE ε4 genotype and other relevant cova-
riates. This highlights the importance of consideration of
the potential effects of smoking status on AD-related neuro-
pathology. Smokers and never smokers from this cognitively
normal cohort will be compared on markers of structural,
metabolic, OxS, and neurocognition in future analyses to
more accurately determine the number of individuals exhib-
iting criteria for the various preclinical AD stages.
The 11% active smokers in this cohort is consistent with
the estimated prevalence of 10% active smokers in those
60 years of age in the general US population [2]. It is note-
worthy that 89% of smokers were former smokers, with a
wide range of duration of smoking cessation. The lack of dif-ferences between smokers and never smokers on CVD and
cerebrovascular disease risk factors (e.g., triglyceride and
cholesterol levels, modified Hachinski score, use of antihy-
pertensive medications) may be related to the fact that
89% of the smokers were former smokers or potentially to
survivor bias in the smoker cohort. Nevertheless, despite
346 15 years of smoking cessation, former smokers demon-
strated significantly greater florbetapir retention in the
cingulate, temporal, parietal, and composite GM. In the
entire smoker sample and in former smokers alone, there
were no significant associations between cigarette exposure
variables and regional florbetapir retention. These findings
suggest that other premorbid and/or comorbid factors not
considered in this report may have partially contributed to
the greater regional florbetapir retention observed in
smokers, or the amyloid deposition in this cohort has been
stable for many years. Given the increased rate of amyloid
accumulation is associated with an increased risk for cogni-
tive decline in cognitively normal elders, as well as for con-
version from MCI to AD [234,235], longitudinal tracking of
this cohort of smokers and never smokers may advance our
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dementia incidence in the rapidly growing numbers of the
oldest-old (i.e.,90 years of age) in the United States [236].
8. Summary
1. The cumulative body of research considered in this re-
view strongly indicates that a history of smoking (i.e.,
former and active) is a significant and modifiable risk
factor for AD, and increasing smoking exposure is
related to greater AD risk. Smoking is associated
with earlier onset of AD symptomatology and is esti-
mated to account for 4.7 million AD cases worldwide.
In the United States, smoking is associated with at
least a 10-year reduction in life expectancy [237],
which will decrease the number of elder smokers
participating in both case-controlled and cohort
studies, and creates a survivor bias due to premature
death. In other words, the study of smoking-related
risk for AD in elders will be inescapably biased toward
the healthiest smokers—individuals who survived or
did not experience significant smoking-related
morbidity [91,92]. Furthermore, Chang et al. [92]
clearly demonstrated how competing risk due to death
(i.e., a smoker dies of another cause before manifest-
ing AD) may obscure the association between smok-
ing and risk for AD. The development of common
clinically significant smoking-related morbidity
(e.g., CVD, COPD, cancer, multiple cerebrovascular
accidents) may be exclusionary in some studies or
limit the functional ability and/or motivation of indi-
viduals to participate in longitudinal studies. This
may also create a selection bias in which the character-
istics of study participants free from these conditions
are not representative of the comparably aged smokers
in the general population. Taken together, the actual
magnitude of risk for AD associated with smoking is
likely underestimated because of survivor bias.
2. Chronic exposure to cigarette smoke and nicotine is
consistently and causally linked to OxS in vitro and
in animal models and is associated with OxS and corre-
sponding cerebral cellular damage in postmortem hu-
man studies. The animal models used a wide variety
of smoke exposure levels and durations, which should
be considered when interpreting the findings from these
studies. OxS is related to increased activity of the pro-
teolytic pathway responsible for generating Ab iso-
forms, as well as abnormal tau phosphorylation.
Therefore, exogenous sources of OxS may facilitate
the onset of AD pathophysiology/neuropathology,
rather than simply emerge as a physiological conse-
quence of existing amyloid or tau pathology. Given
the strong association between cigarette smoke expo-
sure and increased brain OxS, smoking in humans
may serve as a fundamental mechanism promotingdevelopment of AD pathophysiology and neuropa-
thology. This assertion is supported by (1) in vitro
data demonstrating chronic cigarette smoke condensate
exposure and nicotine to various cell types is causally
related to increased cerebral Ab isoforms and p-tau
concentrations; (2) data from animal studies showing
cigarette smoke exposure causally increases brain
fibrillar Ab deposition and nicotine administration pro-
moted p-tau levels; and (3) data from large–sample size
human postmortem studies and our novel in vivo PET
neuroimaging findings (see Section 7) showing that
cognitively normal former/active smoking is robustly
associated with significantly increased cortical fibrillar
amyloid deposition (former/active smokers and never
smokers were also equivalent on cerebrovascular risk
factors in our cohort). Taken together, smoking-
related OxS may increase the risk for AD through the
initiation and progression of the core amyloid and tau
pathologies that are hypothesized to lead to neurode-
generation, cell death, and neurocognitive decline.
3. Pure nicotine administration in vitro and in animal
models yielded variable findings for Ab pathology
but consistent results for tau pathology. In humans,
we are not aware of any published in vivo or postmor-
tem studies on the effects of pure nicotine consump-
tion on AD pathophysiology. In animals, chronic
nicotine administration was shown to significantly
decrease neuritic plaques and insoluble Ab1-40 and
Ab1-42 levels in the cortex or hippocampus but did
not alter soluble Ab1-40 and Ab1-42 concentrations in
these regions. The findings for the soluble Ab iso-
forms are significant for humans because soluble Ab
oligomer levels may be more strongly related to cogni-
tive decline and tau hyperphosphorylation than
fibrillar Ab-containing compounds. In vitro exposure
of nicotine and nicotine agonists causally increased
p-tau and total tau levels, and in animals, chronic nico-
tine administration causally and significantly
increased hippocampal tau aggregation and phosphor-
ylation. The animal research reviewed used a wide va-
riety of animal types (e.g., mice, rats, transgenic
animals) and routes of nicotine administration and
dosages, which may have contributed to the variability
of the findings in these preclinical studies. In humans,
a7 nAChR agonists increased PiB binding (shows
high affinity binding to fibrillar amyloid), postmor-
tem, in frontal lobe homogenates of elder AD and con-
trols. Currently, the combined findings from animal
and human studies do not provide consistent evidence
that nicotine and other a7 nAChR agonists are protec-
tive against Ab deposition. Importantly, in vitro and
animal models showed administration of nicotine
and nAChR agonists consistently and causally
induced tau hyperphosphorylation and aggregation.
The association between nicotine administration and
T.C. Durazzo et al. / Alzheimer’s & Dementia 10 (2014) S122-S145S136abnormal tau phosphorylation is consistent with nico-
tine serving as a source of OxS.
4. Smoking in clinical and nonclinical cohorts across
adulthood is strongly related to multiple neurobiolog-
ical and neurocognitive abnormalities (see Section 4).
In humans, smoking is consistently associated with
biomarkers of compromised neuronal integrity and
degeneration (e.g., regional volume loss, cortical thin-
ning, decreased N-acetylaspartate levels) and neuro-
cognitive deficiencies. Smoking-related deficiencies
in learning/memory, processing speed, and executive
skills, as well as regional brain structural abnormal-
ities may show progression over time in the middle-
aged to elder adults. In cognitively normal elders,
several of the reviewed postmortem studies indicated
that smokers showed significant Ab deposition and
increased tau pathology. Additionally, we observed
that cognitively normal elder controls with a history
of smoking demonstrated significantly higher reten-
tion of florbetapir, a marker of fibrillar Ab deposition,
in multiple brain regions. Taken together, several of
these neurobiological and neurocognitive abnormal-
ities exhibited by cognitively normal middle-aged
and elder adults are consistent with the recently pro-
posed preclinical stages of AD (see Section 7.4 for
description of pathology associated with each stage)
[27,49]. It is important to recognize that some of the
neurobiological and neurocognitive abnormalities
demonstrated may also be, least partially, related to
unrecognized genetic and/or premorbid/comorbid
factors, rather than solely to the effects of smoking
[14,112,129].
5. The relationship between midlife smoking and risk for
AD may also be influenced by potential differences
between smokers and nonsmokers on brain reserve,
cognitive reserve [238], and other unrecognized ge-
netic and/or premorbid/comorbid factors, as well as
other modifiable factors such as diet, physical activity,
and cognitive engagement [14,70]. Smoking is
associated with an increased risk for CVD [13] and ce-
rebrovascular disease [167,239]; OxS is suggested as a
mechanism for both CVD and cerebrovascular disease
[94,141]. Because individuals with AD frequently
manifest evidence of cerebrovascular pathology
(e.g., WM hyperintensities/lesions, subcortical
nuclei lesions) [240,241], smoking-related OxS also
potentially contributes to an increased risk for AD
via CVD/cerebrovascular disease (i.e., atherosclerosis
and associated vascular dysfunction) [70,73], rather
than exclusively through the facilitation of the
amyloidogenic pathway. However, compromised
cerebrovascular function may also be related to
CAA, which is more severe and widespread across
the brain in APOE ε4 carriers [52]. The reviewed
in vitro and preclinical animal findings, indicate thatboth cigarette smoke condensate and smoke exposure
causally facilitate the amyloid and tau pathologies,
and healthy young/middle-aged adults exhibit signifi-
cant neurobiological and neurocognitive abnormal-
ities that are apparent in the preclinical stages of AD
(see Section 4.3). Therefore, smoking-related subclin-
ical or clinically significant CVD and/or cerebrovas-
cular diseases may contribute to, but likely do not
completely account for, the link between midlife
smoking and increased risk for AD.
6. Approximately 31% of active military personnel are
active smokers, which is 11% higher than in the gen-
eral US population, and cigarette use approaches
35% in personnel with high combat exposure. Smok-
ing in active duty personnel is clearly linked to
decreased combat readiness and diminished general
health [8,11,242]. TBI and posttraumatic stress
disorder (PTSD) are prevalent conditions in active
duty personnel serving in Iraq and Afghanistan, and
increasing evidence suggests that these conditions
increase the risk for AD [243]. Smoking is a highly co-
morbid condition in TBI [129], PTSD [200], and other
anxiety disorders [244]; consequently, it is imperative
to consider the potential mediating or moderating ef-
fect of the smoking status on the association between
TBI, PTSD, and the risk for AD in future case-
controlled or cohort studies. The smoking-related
neurobiological and neurocognitive abnormalities
observed in nonclinical cohorts of late adolescents
through middle-aged adults are highly relevant for
the US Armed Services, given most active duty
personnel are between the ages of 18 and 50 years.
Additionally, the neurobiological and/or neurocogni-
tive sequelae associated with both mild TBI and haz-
ardous alcohol consumption appear to be
exacerbated by smoking, and diminished recovery
from these conditions is associated with smoking.
These findings are of critical import to the US Armed
Services because of the significantly increased risk for
mild TBI and hazardous levels of alcohol consump-
tion in active duty personnel. The Department of De-
fense (DoD) clearly recognizes the adverse effects of
smoking on the well-being of active duty personnel
[9] and has promoted the “Quit Tobacco. Make
Everyone Proud” education campaign. Also, the
Code of Federal Regulations, Title 32, Part 85, specif-
ically outlines DoD policies to prevent smoking and
encourage cessation, which dictate that each armed
service develop its own health promotion plans [8].
However, the efficacy of such programs and policies
have been questioned, and unfortunately, there
currently appears to be many logistical and political
issues that obstruct the enactment of more stringent to-
bacco control in the US Armed Services [8,10–
12,242].
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 Currently, the interplay between APOE genotype
and smoking on risk for AD is unclear and requires
further prospective cohort-based research.
 Additional prospective longitudinal studies with
former smokers that are fully characterized on
smoking exposure variables, cessation periods,
diet, and exercise are necessary to better understand
the association between former smoking status/
smoking cessation and risk for AD.
 The association between smoking and risk for MCI
has received little attention [245,246] and warrants
future research because MCI is considered to be the
prodromal stage of AD [28,247].
 Longitudinal in vivo measurements of multiple bio-
markers of brain Ab burden, tau, and OxS in
smokers and nonsmokers during middle age (i.e.,
40-65 years of age) will promote a better under-
standing on how smoking relates to the onset
and trajectory of AD pathophysiology and neuropa-
thology. The interplay between nicotine/cholinergic
agonists at nAChRs and Ab- and tau-related neuro-
pathology is clearly multifaceted, and additional
prospective research is needed to clarify their ef-
fects on AD-related neuropathology and utility as
potential disease-modifying agents. These research
objectives may be accomplished via florbetapir for
fibrillar amyloid, new PET tracers for tau [248],
and with magnetic resonance spectroscopy of gluta-
thione concentration, an established marker of OxS
[249]. Alternately, concurrent measurement of CSF
concentrations of Ab and tau isoforms combined
with CSF isoprostanoids, a measure of ROS-
mediated OxS (see Refs. [141,154,250] for
review), may also provide parallel information.
Additionally, examination of the association
between smoking and soluble Ab oligomers (e.g.,
Ab trimers, Ab*56) may be informative as recent
research has reported the strong relationships
between these oligomers and age, neurocognition,
neuritic plaque load, and soluble tau levels
[58,251].9. Conclusions
 The cumulative body of research to date indicates that
previous and active smoking is associated with a
significantly increased risk for AD, and previous
research reporting that smoking was related to a signif-
icantly decreased risk for AD appears to be highly
confounded by selection/survivor bias and affiliation
with the tobacco industry. Correspondingly, in humans,
there is no consistent evidence demonstrating that
smoking or pure nicotine confers any protection fromthe development of AD neuropathology or is associ-
ated with a decreased risk for AD.
 Late-onset AD is characterized by an extended preclin-
ical stage, and smoking has been associated with
earlier onset of AD symptomatology. We hypothesize
that smoking during middle age, via chronic OxS,
may shorten the length of the preclinical period by
shifting the inception of AD-related pathologic Ab
processing, tau protein hyperphosphorylation, and,
potentially, mild cerebrovascular dysfunction (via sub-
clinical cerebrovascular disease and/or CAA) to a
significantly younger age. We predict that the greatest
AD pathologic findings will be most apparent in
actively smoking APOE ε4 carriers.
 CVD, stroke, diabetes, hypertension, and hypercholes-
terolemia have been individually proposed as potential
modifiable risk factors for AD [25,70,252], and these
conditions are also associated with an increased risk
for vascular dementia [253,254]. Because smoking is
moderately to strongly associated with an increased
risk for the development of the aforementioned
medical conditions [13,70,206,255], a global
decrease in the prevalence of smoking would also
likely promote a further reduction in the number of
people who develop and suffer from AD [70,206]
and vascular dementia.
 The significantly increased risk for smoking-related
CVD, COPD, and cancer has been recognized by
most health-care providers and the general public for
decades, but, unfortunately, tobacco use is treated at
a much lower frequency than other chronic conditions
(e.g., diabetes, hypertension) [256]. Additionally, it has
been argued that if health-care providers have the
perception that smoking does not increase the risk
for, or is somehow protective of, AD, this may serve
as an additional barrier to encourage engagement in
smoking cessation interventions, particularly in elders
[206]. The aforementioned may act in concert to
contribute to the general undertreatment of tobacco
use in the United States, which may have even greater
adverse ramifications for active duty military
personnel, given their higher prevalence of smoking.
We fully recognize the challenges associated with
maintenance of sustained smoking cessation with
currently available behavioral and pharmacological in-
terventions [7,257]; however, more aggressive global
efforts aimed at smoking prevention in youth and
facilitation of sustained smoking cessation in adults
may ultimately promote a significant decrease in the
prevalence of future AD cases worldwide.
 Considering multiple studies observed former smok-
ing (i.e., individuals who quit) during lifetime was
associated with AD-related neuropathology and
increased risk for AD, we strongly support that the
FDA Family Smoking Prevention and Tobacco
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bacco product advertising and marketing to youth to
prevent the onset of smoking. We also support more
vigorous efforts by the DoD to incentivize new US
Armed Service recruits not to smoke and active duty
personnel to stop smoking.
 Given there are no currently available pharmacological
interventions that prevent the onset of AD pathophys-
iology or significantly alter its clinical course, it is
imperative to delineate the mechanisms by which
potentially “modifiable” risk factors, such as smoking,
confer increased risk for AD during the preclinical
stages. This will assist in the identification of those at
elevated AD risk and potentially inform development
of more efficacious treatment interventions [27]. Spe-
cifically, if we understand how smoking increases the
risk for AD during the preclinical stages, the associated
pathophysiological mechanisms (e.g., OxS) [203] may
be mitigated through targeted treatment, or more
ideally, the mechanisms halted via smoking cessation.
Furthermore, determining if smoking is associated
with greater AD-related pathophysiology and neuropa-
thology during the specific preclinical AD stages is
highly relevant, as those who are in stages 1 to 3 may
be at risk for clinically significant cognitive and func-
tional decline over time [258]. Prospective longitudinal
research specifically focusing on the neurobiological
consequences of smoking (including the potential in-
teractions among smoking status, age, APOE geno-
type, and other emerging AD risk factors), as well as
the neurobiological effects of sustained smoking cessa-
tion, in adolescents to elders, is clearly warranted and
necessary to delineate the potential mechanisms by
which smoking places individuals at greater risk for
AD. The study of young to middle-aged adults has
the advantage of minimizing the likelihood of clini-
cally significant smoking-related diseases [259] that
may affect brain neurobiology and contribute to survi-
vor bias. Such research must also be conducted to bet-
ter inform and change perceptions among health-care
providers, civilians, veterans, and active duty military
about the adverse effects of smoking on the brain and
its functions. Finally, expanded research efforts
focusing on the longitudinal neurobiological and neu-
rocognitive consequences of chronic smoking in con-
ditions in which it is highly prevalent (e.g., AUDs,
schizophrenia-spectrum disorders, mood disorders,
PTSD) are required to further inform policy on regula-
tion of the manufacture, distribution, and marketing of
tobacco products in the United States and abroad.Acknowledgments
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